NVCR

$0.00

(

0.00%

) Quote details
Add to Watchlist Run Backtest
stock

Novocure Ltd

NASDAQ | NVCR

11.32

USD

$0.00

(

0.00%

)

At Close (As of Nov 14, 2025)

$1.27B

Market Cap

-

P/E Ratio

-1.61

EPS

$34.13

52 Week High

$10.70

52 Week Low

HEALTHCARE

Sector

NVCR Chart

Recent Chart
Price Action

NVCR Technicals

Tags:

NVCR Earnings

Yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit $468M
Total Revenue $605M
Cost Of Revenue $137M
Costof Goods And Services Sold $137M
Operating Income -$170M
Selling General And Administrative $190M
Research And Development $210M
Operating Expenses $639M
Investment Income Net -
Net Interest Income $40M
Interest Income $23M
Interest Expense $12M
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $11M
Income Before Tax -$131M
Income Tax Expense $37M
Interest And Debt Expense -
Net Income From Continuing Operations -$169M
Comprehensive Income Net Of Tax -
Ebit -$119M
Ebitda -$108M
Net Income -$169M

Revenue & Profitability

Earnings Performance

NVCR Financials

yearly Balance Sheet (As of Dec 31, 2024)

Field Value (USD)
Total Assets $1.2B
Total Current Assets $1.1B
Cash And Cash Equivalents At Carrying Value $164M
Cash And Short Term Investments $164M
Inventory $35M
Current Net Receivables $102M
Total Non Current Assets $134M
Property Plant Equipment -
Accumulated Depreciation Amortization Ppe -
Intangible Assets -
Intangible Assets Excluding Goodwill -
Goodwill -
Investments -
Long Term Investments -
Short Term Investments $796M
Other Current Assets $9.5M
Other Non Current Assets -
Total Liabilities $881M
Total Current Liabilities $756M
Current Accounts Payable $105M
Deferred Revenue -
Current Debt -
Short Term Debt $566M
Total Non Current Liabilities $124M
Capital Lease Obligations $28M
Long Term Debt $97M
Current Long Term Debt $558M
Long Term Debt Noncurrent -
Short Long Term Debt Total $683M
Other Current Liabilities $71M
Other Non Current Liabilities $18K
Total Shareholder Equity $360M
Treasury Stock -
Retained Earnings -$1.2B
Common Stock -
Common Stock Shares Outstanding $108M

yearly Cash Flow (As of Dec 31, 2024)

Field Value (USD)
Operating Cashflow -$26M
Payments For Operating Activities -
Proceeds From Operating Activities -
Change In Operating Liabilities -
Change In Operating Assets -
Depreciation Depletion And Amortization -$14M
Capital Expenditures $43M
Change In Receivables -
Change In Inventory $2.6M
Profit Loss -
Cashflow From Investment -$140M
Cashflow From Financing $90M
Proceeds From Repayments Of Short Term Debt -
Payments For Repurchase Of Common Stock -
Payments For Repurchase Of Equity -
Payments For Repurchase Of Preferred Stock -
Dividend Payout -
Dividend Payout Common Stock -
Dividend Payout Preferred Stock -
Proceeds From Issuance Of Common Stock -
Proceeds From Issuance Of Long Term Debt And Capital Securities Net -
Proceeds From Issuance Of Preferred Stock -
Proceeds From Repurchase Of Equity -
Proceeds From Sale Of Treasury Stock -
Change In Cash And Cash Equivalents -
Change In Exchange Rate -
Net Income -$169M

yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit $468M
Total Revenue $605M
Cost Of Revenue $137M
Costof Goods And Services Sold $137M
Operating Income -$170M
Selling General And Administrative $190M
Research And Development $210M
Operating Expenses $639M
Investment Income Net -
Net Interest Income $40M
Interest Income $23M
Interest Expense $12M
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $11M
Income Before Tax -$131M
Income Tax Expense $37M
Interest And Debt Expense -
Net Income From Continuing Operations -$169M
Comprehensive Income Net Of Tax -
Ebit -$119M
Ebitda -$108M
Net Income -$169M

NVCR News

NVCR Profile

Novocure Ltd Profile

Sector: HEALTHCARE

Industry: MEDICAL DEVICES

Novocure Ltd is an innovative oncology company headquartered in Saint Helier, Jersey, that is at the forefront of cancer treatment with its proprietary tumor-treating fields (TTFields) therapy, exemplified by its flagship product, Optune. This groundbreaking technology disrupts cancer cell division, currently approved for use in treating glioblastoma multiforme and mesothelioma. With a strong focus on expanding its clinical trial portfolio and research initiatives, Novocure is committed to advancing its leadership position in the oncology market by developing transformative therapies that address critical unmet medical needs in cancer care.

WTO
+19.50%
$0.02
LPTX
+368.57%
$2.05
ASBP
+1.04%
$0.10
AMZE
+1.80%
$0.40
VINE
+1.80%
$0.40
EPWK
+16.62%
$0.04
VHAI
+33.33%
$0.00
NVDA
+1.77%
$190.17
ONDS
+9.45%
$7.18
IVVD
+32.76%
$2.35
BYND
+6.93%
$1.08
ASST
-6.08%
$1.08
CHR
+1.67%
$0.04
TSLA
+0.58%
$404.35
PFE
-2.83%
$25.06
SOFI
-2.00%
$27.82
PLUG
-9.83%
$2.24
BITF
-0.76%
$2.58
NVVE
-45.37%
$0.25
ACHR
-1.00%
$7.88
ETHD
+1.75%
$5.23
INTC
-1.08%
$35.52
RGTI
+1.11%
$25.48
F
-0.67%
$13.19
AXDX
-61.36%
$0.03
PLTR
+1.08%
$174.01
RIVN
-7.80%
$15.11
TLRY
-4.42%
$1.08
CIFR
-3.81%
$14.36
SNAP
-0.11%
$8.57
WULF
-5.90%
$10.99
NIO
-1.28%
$6.16
WBD
+4.01%
$23.03
CRWV
-1.25%
$77.36
QBTS
+0.94%
$23.61
IONZ
-8.28%
$5.20
ADAP
-15.14%
$0.05
DNN
-0.40%
$2.48
BMNR
-5.93%
$34.40
DVLT
+18.83%
$1.83
IREN
-4.68%
$46.37
MARA
-6.18%
$11.99
AMD
-0.46%
$246.81
AAPL
-0.19%
$272.41
DFLI
+4.85%
$0.81
MKDW
-18.20%
$0.16
APLD
+2.55%
$23.65
APLT
-19.14%
$0.21
CLSK
-8.51%
$10.96
GRAB
-2.34%
$5.41
CAN
-8.04%
$0.89
RMBL
+60.50%
$3.21
AMZN
-1.21%
$234.69
LNW
-3.71%
$86.22
CSCO
+0.80%
$78.00
ADD
-25.47%
$0.05
QUBT
+5.68%
$10.60
CRCL
-0.54%
$81.89
T
-0.62%
$25.59
SMCI
+3.79%
$36.42
MU
+4.16%
$246.83
ORCL
+2.42%
$222.85
BTG
0.00%
$4.10
SRM
+53.27%
$10.30
KVUE
-0.65%
$16.66
BABA
-3.77%
$153.80
AAL
-2.37%
$12.76
BBD
+0.54%
$3.68
BAC
-0.49%
$52.61
HOOD
+0.79%
$122.50
NBIS
-5.74%
$83.54
GPUS
-7.60%
$0.27
RIOT
+0.50%
$13.95
GOOGL
-0.77%
$276.41
HIMS
+2.57%
$36.98
RXRX
-4.38%
$4.14
NOK
-0.73%
$6.73
JD
-4.55%
$29.31
PLTZ
-2.27%
$6.88
PLTD
-1.01%
$6.84
HPE
-0.43%
$22.83
QS
-1.03%
$13.43
BTBT
-4.36%
$2.41
IONQ
+3.92%
$47.18
VZ
-0.12%
$41.06
RIG
0.00%
$4.01
WLGS
-5.57%
$0.04
MSFT
+1.36%
$510.18
SOUN
-0.40%
$12.17
MTSR
-0.35%
$70.50
XPON
-8.66%
$1.16
XPEV
-5.19%
$25.01
BURU
-2.77%
$0.24
ABEV
+1.19%
$2.55
BTE
+0.63%
$3.16
SMR
-3.02%
$22.45
RGTZ
-2.55%
$27.42
DEFT
-15.17%
$1.23
VALE
-0.64%
$12.30
EOSE
-9.24%
$13.80
WTO
+19.50%
$0.02
LPTX
+368.57%
$2.05
ASBP
+1.04%
$0.10
AMZE
+1.80%
$0.40
VINE
+1.80%
$0.40
EPWK
+16.62%
$0.04
VHAI
+33.33%
$0.00
NVDA
+1.77%
$190.17
ONDS
+9.45%
$7.18
IVVD
+32.76%
$2.35
BYND
+6.93%
$1.08
ASST
-6.08%
$1.08
CHR
+1.67%
$0.04
TSLA
+0.58%
$404.35
PFE
-2.83%
$25.06
SOFI
-2.00%
$27.82
PLUG
-9.83%
$2.24
BITF
-0.76%
$2.58
NVVE
-45.37%
$0.25
ACHR
-1.00%
$7.88
ETHD
+1.75%
$5.23
INTC
-1.08%
$35.52
RGTI
+1.11%
$25.48
F
-0.67%
$13.19
AXDX
-61.36%
$0.03
PLTR
+1.08%
$174.01
RIVN
-7.80%
$15.11
TLRY
-4.42%
$1.08
CIFR
-3.81%
$14.36
SNAP
-0.11%
$8.57
WULF
-5.90%
$10.99
NIO
-1.28%
$6.16
WBD
+4.01%
$23.03
CRWV
-1.25%
$77.36
QBTS
+0.94%
$23.61
IONZ
-8.28%
$5.20
ADAP
-15.14%
$0.05
DNN
-0.40%
$2.48
BMNR
-5.93%
$34.40
DVLT
+18.83%
$1.83
IREN
-4.68%
$46.37
MARA
-6.18%
$11.99
AMD
-0.46%
$246.81
AAPL
-0.19%
$272.41
DFLI
+4.85%
$0.81
MKDW
-18.20%
$0.16
APLD
+2.55%
$23.65
APLT
-19.14%
$0.21
CLSK
-8.51%
$10.96
GRAB
-2.34%
$5.41
CAN
-8.04%
$0.89
RMBL
+60.50%
$3.21
AMZN
-1.21%
$234.69
LNW
-3.71%
$86.22
CSCO
+0.80%
$78.00
ADD
-25.47%
$0.05
QUBT
+5.68%
$10.60
CRCL
-0.54%
$81.89
T
-0.62%
$25.59
SMCI
+3.79%
$36.42
MU
+4.16%
$246.83
ORCL
+2.42%
$222.85
BTG
0.00%
$4.10
SRM
+53.27%
$10.30
KVUE
-0.65%
$16.66
BABA
-3.77%
$153.80
AAL
-2.37%
$12.76
BBD
+0.54%
$3.68
BAC
-0.49%
$52.61
HOOD
+0.79%
$122.50
NBIS
-5.74%
$83.54
GPUS
-7.60%
$0.27
RIOT
+0.50%
$13.95
GOOGL
-0.77%
$276.41
HIMS
+2.57%
$36.98
RXRX
-4.38%
$4.14
NOK
-0.73%
$6.73
JD
-4.55%
$29.31
PLTZ
-2.27%
$6.88
PLTD
-1.01%
$6.84
HPE
-0.43%
$22.83
QS
-1.03%
$13.43
BTBT
-4.36%
$2.41
IONQ
+3.92%
$47.18
VZ
-0.12%
$41.06
RIG
0.00%
$4.01
WLGS
-5.57%
$0.04
MSFT
+1.36%
$510.18
SOUN
-0.40%
$12.17
MTSR
-0.35%
$70.50
XPON
-8.66%
$1.16
XPEV
-5.19%
$25.01
BURU
-2.77%
$0.24
ABEV
+1.19%
$2.55
BTE
+0.63%
$3.16
SMR
-3.02%
$22.45
RGTZ
-2.55%
$27.42
DEFT
-15.17%
$1.23
VALE
-0.64%
$12.30
EOSE
-9.24%
$13.80
2025 © AfterPullback LTD

Charts powered by TradingView

Market data may be delayed by 15 minutes or more and is provided by financial exchanges or third-party providers. AfterPullback does not verify or guarantee its accuracy and assumes no responsibility to do so. This website is not operated by a licensed attorney, accountant, or financial advisor. Nothing on this site constitutes financial advice or replaces consultation with a qualified professional who understands your specific circumstances. Always consult a licensed financial advisor before making investment decisions.